ILF2 and breast cancer: Furthermore, evidence has been presented that H19 depletion increases sensitivity to PARP inhibitors via ILF2 in ER+ breast cancer cells with wild-type BRCA1 and in BRCA1 mutant triple-negative breast cancer cells.